Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma

  • Original Paper
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objectives

The prognosis of patients with platinum refractory disease is dismal. We present data from heavily pretreated patients to whom the folinic acid, 5-fluorouracil and oxaliplatin (Folfox) regimen was administered. The objectives were to assess response rate and to evaluate the safety profile.

Methods

Patients with recurrent, resistant or refractory pretreated ovarian carcinoma were eligible for oxaliplatin (85 mg/m2) and leucovorin (200 mg/m2), both given as a 2-h infusion on day 1, followed by a 48-h infusion of 5FU 2,600 mg/m2 every 2 weeks.

Results

Fourteen patients were treated. Median age: 56 years (49–70). Median number of previous chemotherapy regimens: 5 (3–10) and previous platinum-based regimens: 2 (1–3). Median chemotherapy-free interval (interval since the completion of the last-line chemotherapy before the administration of the Folfox regimen): 9.5 weeks (1–39). Median number of administered cycles of Folfox/patient: 8 (2–11 cycles). Two (14.5%) patients had a disease complete response, 2 (14.5%)—partial response, 4 (29%)—stable disease and 6 (43%)—progressive disease. Four (29%) patients had a CA-125 complete response, 2 (14.5%)—CA-125 partial response, 5 (35.5%)—stable CA-125 levels and 3 (21%)—progressive CA-125 levels. There were no grade 4 adverse events or deaths due to the treatment. No dose modifications were required due to toxicity.

Conclusions

Folfox seems to be a valuable option for heavily pre-treated patients with ovarian cancer, with an overall response rate, according to RECIST criteria, of 29% and disease stabilization in an additional 29% of patients, with a manageable toxicity profile. These results support further assessment of Folfox as salvage treatment for patients with carcinoma of the ovary or fallopian tube.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. US Census Bureau, International Data Base, 2004. http://www.cureresearch.com/o/ovarian_cancer/stats-country.htm

  2. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9(3):389–393

    PubMed  CAS  Google Scholar 

  3. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS et al (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11(12):2405–2410

    PubMed  CAS  Google Scholar 

  4. Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12(12):1705–1709

    Article  PubMed  CAS  Google Scholar 

  5. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A et al (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16(5):749–755

    Article  PubMed  CAS  Google Scholar 

  6. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9(10):1053–1071

    Article  PubMed  CAS  Google Scholar 

  7. Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53(24):5970–5976

    PubMed  CAS  Google Scholar 

  8. Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M et al (2004) Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 95(1):165–172

    Article  PubMed  CAS  Google Scholar 

  9. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947

    PubMed  Google Scholar 

  10. Common Terminology Criteria for Adverse Events, Version 3.0, Revised 10 June, 2003. National Cancer Institute. http://ctep.cancer.gov/forms/CTCAEv3.pdf

  11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  12. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ et al (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14(5):1545–1551

    PubMed  CAS  Google Scholar 

  13. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC et al (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58(16):3579–3585

    PubMed  CAS  Google Scholar 

  14. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23

    Article  PubMed  CAS  Google Scholar 

  15. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56(21):4881–4886

    PubMed  CAS  Google Scholar 

  16. Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH et al (2006) Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecol Oncol 103(2):439–445

    Article  PubMed  CAS  Google Scholar 

  17. Tournigand CCE, Maindrault Goebel F et al (2005) Docetaxel (D) and oxaliplatin (DOCELOX) in advanced ovarian cancer (AOC): preliminary safety results of a phase I–II (meeting abstracts). J Clin Oncol 23. Abstract 5104

  18. Gorbounova VTS, Besova N (2005) Phase II trial of oxaliplatin (OXA) and topotecan (TOP) as a first line treatment for the patients (pts) with advanced ovarian cancer (AOC): preliminary results of a pilot study (meeting abstracts). J Clin Oncol 23. Abstract 5116

  19. Deplanque GGA, Fabbro M et al (2004) Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): preliminary results (meeting abstracts). J Clin Oncol 22. Abstract 5075

  20. Misset JL, Vennin P, Chollet PH, Pouillart P, Laplaige PH, Frobert JL et al (2001) Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol 12(10):1411–1415

    Article  PubMed  CAS  Google Scholar 

  21. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS (2003) Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 21(15):2856–2859

    Article  PubMed  CAS  Google Scholar 

  22. Chevalier ACN, Fumoleau P et al (2003) Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) and/or liposomal doxorubicin based chemotherapy (meeting abstracts). J Clin Oncol 21:463. (Abstract 1861)

    Article  Google Scholar 

  23. Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C et al (2002) Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/− taxane-pretreated ovarian cancer patients. Ann Oncol 13(2):258–266

    Article  PubMed  CAS  Google Scholar 

  24. Vermorken JBGM, Perren T et al (2001) Multicenter randomized phase II study of oxaliplatin (OXA) or topotecan (TOPO) in platinum-pretreated epithelial ovarian cancer (EOC) patients (pts) (meeting abstracts). J Clin Oncol 20. Abstract 847

  25. Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P et al (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18(6):1193–1202

    PubMed  CAS  Google Scholar 

  26. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H et al (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7(10):1065–1070

    PubMed  CAS  Google Scholar 

  27. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH et al (2006) A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 17(3):429–436

    Article  PubMed  CAS  Google Scholar 

  28. Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G et al (2006) Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol 100(2):318–323

    Article  PubMed  CAS  Google Scholar 

  29. Sundar S, Symonds RP, Decatris MP, Kumar DM, Osman A, Vasanthan S et al (2004) Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 94(2):502–508

    Article  PubMed  CAS  Google Scholar 

  30. Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67(5-6):376–381

    Article  PubMed  CAS  Google Scholar 

  31. Ferrandina GLM, Dagostino G et al (2004) Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer (meeting abstracts). J Clin Oncol 22. Abstract 5078

  32. Arca RIJ, Lerzo G et al (2004) Gemcitabine (GEM) 1 oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) 1 paclitaxel (PAC): preliminary report of a phase II study (meeting abstracts). J Clin Oncol 22. Abstract 5111

  33. Germano DBD, Di Nota A et al (2004) Bi-weekly oxaliplatin (oxa) and gemcitabine (gem) in cisplatin pretreated patients with relapsed ovarian cancer (roc): preliminary data of a phase II trial (meeting abstracts). J Clin Oncol 22. Abstract 5104

  34. Dohollou NWB, Geay JF et al (2003) Gemcitabine (GE) and oxaliplatin (OX) in patients with recurrent advanced ovarian cancer in early progression (6 months) (AOCEP): a GINECO phase II trial (meeting abstracts). J Clin Oncol 21:451. (Abstract 1813)

    Google Scholar 

  35. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J et al (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13(9):1479–1489

    Article  PubMed  CAS  Google Scholar 

  36. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM et al (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10(9):1125–1128

    Article  PubMed  CAS  Google Scholar 

  37. Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M et al (1997) Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33(9):1400–1406

    Article  PubMed  CAS  Google Scholar 

  38. Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C et al (2006) A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 16(Suppl 1):79–85

    Article  PubMed  Google Scholar 

  39. Seliger GML, Buechele T et al (2002) Salvage chemotherapy with docetaxel, oxaliplatin and gemcitabine in platinum-pretreated advanced epithelial ovarian cancer: preliminary results of a phase II study (meeting abstracts). J Clin Oncol 20. Abstract 864

  40. Osman ATA, Morgan B et al (2001) Phase II study of oxaliplatin (OXA) and 5-fluorouracil (5FU) in patients with relapsed ovarian cancer (ROC). J Clin Oncol 20. Abstract 2502

  41. Delaloge S, Laadem A, Taamma A, Chouaki N, Cvitkovic E, Pautier P et al (2000) Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol 23(6):569–574

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None to disclose.

Author information

Authors and Affiliations

  1. Department of Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium

    Daniela D. Rosa, Ahmad Awada, Max S. Mano, Jean Selleslags, Fabienne Lebrun, Thierry Gil, Martine J. Piccart & Véronique D’Hondt

  2. Hospital Fêmina and Hospital Moinhos de Vento, Porto Alegre, Brazil

    Daniela D. Rosa

  3. Postgraduate Program in Medicine: Medical Sciences at Federal University of Rio Grande do Sul, Porto Alegre, Brazil

    Daniela D. Rosa

  4. Rua André Puente 185/204, Porto Alegre, Brazil

    Daniela D. Rosa

Authors
  1. Daniela D. Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmad Awada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max S. Mano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Selleslags
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabienne Lebrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thierry Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martine J. Piccart
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Véronique D’Hondt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela D. Rosa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosa, D.D., Awada, A., Mano, M.S. et al. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet 278, 457–462 (2008). https://doi.org/10.1007/s00404-008-0592-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-008-0592-9

Keywords

Search

Navigation